Eterna Home Launches Summer 2025 Teak Collection, Bringing Sustainable Luxury to British Gardens
Droitwich, United Kingdom--(Newsfile Corp. - April 7, 2025) - Eterna Home, a trusted name in sustainable and high-quality outdoor furnishings, is proud to announce the launch of its Summer 2025 Teak Collection. Designed to elevate British gardens with enduring beauty and natural elegance, this collection introduces a refined range of furniture made from responsibly sourced teak-timed perfectly for the outdoor season ahead.
Eterna Home
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9032/247614_78494fe6745749c8_001full.jpg
Renowned for its dedication to craftsmanship, Eterna Home's new range offers thoughtfully designed pieces that blend timeless style with functionality. Whether for laid-back summer lounging, garden entertaining, or simply enjoying a moment of calm outdoors, each product is crafted to enrich the outdoor living experience.
"Our Summer 2025 Collection represents everything we stand for-sustainability, style, and substance," said Jimmy Bhardwaj, Marketing Consultant at Eterna Home. "We believe outdoor furniture should be as considered and beautifully made as anything found indoors. This new range allows our customers to create garden spaces that are both inviting and built to last."
Eterna Home
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/9032/247614_78494fe6745749c8_002full.jpg
Central to the collection is the elegant teak garden table series, which includes a variety of designs from compact round tables to larger rectangular styles perfect for summer dining. Made from mature teak wood, each table develops a natural patina over time while maintaining exceptional structural strength.
Complementing these tables are Eterna Home's latest teak garden bench models, crafted with ergonomic contours and enduring charm. These benches provide a tranquil seating solution for gardens, courtyards, and terraces-ideal for both decorative and practical purposes.
For a complete outdoor setup, Eterna Home also offers coordinated teak garden set combinations. These sets pair tables with matching chairs or benches, delivering fully styled arrangements that turn any garden into a space for social connection and relaxation.
What sets Eterna Home apart is not just the quality of its designs but also the brand's unwavering commitment to environmental responsibility. All teak used in its furniture is ethically sourced from certified sustainable forests, and the production process emphasizes longevity and low maintenance-an eco-friendly alternative to fast furniture.
The Summer 2025 Teak Collection is now available to browse on Eterna Home's official website, with each piece reflecting the brand's vision of mindful luxury and outdoor living that lasts. Homeowners are invited to explore the new range and find inspiration to reimagine their gardens with authentic, hand-finished teak furniture.
Media Contact:
Jimmy Bhardwaj
Marketing Consultant
Eterna Home
The Oakley, Kidderminster Road
Droitwich, WR9 9AY
info@eternahome.co.uk
01905 928 398
About Eterna Home:
Eterna Home specializes in premium, sustainably sourced teak outdoor garden furniture. With a focus on expert craftsmanship and timeless design, the company offers durable, eco-conscious solutions for homeowners who value quality and beauty in their garden spaces.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
7 hours ago
- Cision Canada
Smart Healthcare Is Taking Over. Here's Where the Money's Headed
VANCOUVER, BC, June 10, 2025 /CNW/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI tools. But as implementations increase across the sector, so too are major developments coming from innovators, including Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL), Omada Health, Inc. (NASDAQ: OMDA), and Inc. (NASDAQ: AMZN). McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. Statista now projects the global AI healthcare market will soar from $11 billion to $188 billion by 2030. Avant Technologies, Inc. (OTCQB: AVAI) has just taken a major step forward in its evolution from AI incubator to full-stack healthcare innovator. Today, the company announced it had signed a non-binding letter of intent to acquire 100% of Ainnova Tech, its joint venture partner and the developer of the Vision AI diagnostic platform. Prior to the acquisition, the two companies have been operating jointly through Ai-nova Acquisition Corp (AAC), which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments. "We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of AAC. "We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare." Under the proposed agreement, Ainnova would roll all of its outstanding equity into the combined public entity — unifying leadership and eliminating structural complexity ahead of a scheduled FDA pre-submission meeting in July. While final terms of the deal are still being negotiated, both companies say the merger would streamline commercialization and accelerate the rollout of Ainnova's flagship Vision AI technology — a platform already in use across clinical sites in Latin America for the early detection of diabetic retinopathy, cardiovascular disease, and other chronic conditions. The move also signals growing confidence from Avant's leadership as they prepare to bring proprietary hardware into the mix. In parallel with the merger discussions, Avant and Ainnova are entering the final prototyping stage of a low-cost, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics. The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel. The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics. "The cost of a fundus camera has always been a barrier to entry in this market," said Vargas. "Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market." Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare. "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care. Renovaro Inc. (NASDAQ: RENB) recently announced a major expansion to its intellectual property portfolio with a newly approved U.S. patent for its AI-powered drug discovery and diagnostics infrastructure. "This patent is a strategic milestone for Renovaro," said David Weinstein, CEO of Renovaro. "Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights." The patent protects methods that harmonize genomic, imaging, clinical, and health record data into a standardized framework for large-scale predictive analytics. These capabilities are built for distributed computing environments, aligning with the biopharma industry's move toward real-time, scalable analytics. The development enhances Renovaro's competitive positioning in data-driven therapeutics and clinical insight markets. Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL) recently showcased its leadership in AI-driven cancer research at the 2025 ASCO Annual Meeting, where Ruth Porat discussed Alphabet's evolving role in early diagnosis and treatment. "AI has greater potential than the internet, because it can augment human capabilities," wrote Ruth Porat, President & Chief Investment Officer of Alphabet and Google, quoting Vint Cerf. "It is a partner for all of you, for each of us." Porat highlighted Google's success with AlphaFold, which has accelerated cancer drug discovery by solving the decades-long problem of protein folding. She also noted the company's AI-assisted pathology tools that cut diagnostic time in half and improve detection of small metastases. From scalable diabetic retinopathy screening to generative AI for clinical workflows, she framed AI as a transformative force in healthcare delivery. Omada Health, Inc. (NASDAQ: OMDA) entered the public markets with a strong debut, raising $150 million and closing its first trading day 21% above IPO pricing. The company delivers AI-augmented virtual care for chronic conditions like diabetes, hypertension, and obesity, serving more than 679,000 active members. In May, prior to the IPO, Omada introduced Nutritional Intelligence, a new member experience powered by OmadaSpark—an AI agent that offers personalized, evidence-based nutrition coaching between clinical visits. As demand rises for GLP-1 medications, Omada is positioning its human-plus-AI model as essential to long-term metabolic health. "We believe there is a clear market need for real-time educational support backed by behavioral science to improve mindsets and behaviors toward food," said Wei-Li Shao, President at Omada Health. "To meet the needs of our customers and members, Omada fine tuned its approach to offer AI-powered tools trained with clinical input and expertise to work alongside human care teams in helping members drive improved health and economic outcomes." Inc. (NASDAQ: AMZN) continues to scale its digital health footprint via Amazon Web Services (AWS), which recently brought its HealthLake platform to the EU's Dublin Region. The move enables hospitals and insurers to unify siloed patient data using FHIR standards, while running AI-driven analytics and maintaining full data residency compliance. "I'm excited about AWS HealthLake launch in EU Region," said Ramon Postulart, CTO at Adapcare. " AWS HealthLake is a key AWS healthcare service helping us modernize interoperability across the 70+ care organizations and 60,000 health professionals we support in the Netherlands. By moving to this service, we're unlocking richer, standardized health data and leveraging the HealthLake fully managed capabilities to build smarter, AI-powered tools for care planning and coordination." HealthLake now serves as the engine behind personalized care tools in development across Ireland, the Netherlands, and Finland. AWS also hosted its Health Data & AI Day in Dublin to promote cross-border health data innovation and the European Health Data Space initiative. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Winnipeg Free Press
8 hours ago
- Winnipeg Free Press
Man City signs backup goalkeeper Bettinelli from Chelsea
MANCHESTER, England (AP) — Manchester City signed Marcus Bettinelli from Chelsea as a backup goalkeeper on Tuesday. City made the move after announcing the departure of long-term No. 3 goalie Scott Carson on Monday with his contract due to expire. Bettinelli has joined on a one-year deal and in time to be involved in the Club World Cup in the United States starting on Saturday. 'His experience and mentality will hopefully complement our other senior goalkeepers while ensuring he's always ready to perform when called upon himself,' City director of football Hugo Viana said. It's City's second signing of this special June 1-10 transfer window introduced to help clubs shape their squads for the Club World Cup. The first was Algeria left back Rayan Ait-Nouri from Wolverhampton for $42 million. British media reported City is also trying to sign midfielders Rayan Cherki and Tijjani Reijnders. ___ AP soccer:
Ottawa Citizen
14 hours ago
- Ottawa Citizen
Raises, retention bonuses promised for Canadian Forces personnel
Article content Pay increases for military personnel as well as retention bonuses and increased training allowances for particular Canadian Forces members are to be part of the government's spending boost for defence. Article content In addition, it is expected that around 1,400 new staff will be hired at the Department of National Defence. Article content Article content The initiatives were outlined Monday during a technical briefing that followed Prime Minister Mark Carney's announcement that defence spending was being significantly increased. The Liberal government noted that it was pumping in more funding so Canada will meet the NATO spending target of two per cent of GDP by the end of this fiscal year. Article content Article content Carney repeated his election promises to purchase new submarines and other equipment as well as improve military housing and benefits. Article content 'Members of our armed forces will get a well deserved salary increase, which will contribute to better recruitment and retention of personnel,' said Carney. Article content But defence officials at the technical briefing had few answers. Article content They did point out that not only will there be pay increases but in some cases boosts in training allowances and retention bonuses for key military personnel. They did not have information on what specific Canadian Forces jobs or trades would be eligible for bonuses. Article content More health-care workers will be hired for the Canadian Forces and the civilian workforce will be expanded so military personnel can focus on operations, government officials said at the technical briefing. Under government-imposed rules, the officials who provided the briefing cannot be identified. Article content Article content In January, the Ottawa Citizen reported that military staff were recommending retention bonuses to keep key personnel from leaving the ranks. But there were questions at the time about whether the government would fund such a plan. Article content Article content Although the Canadian Forces doesn't currently have retention bonuses, the military does offer various extra pay or allowances for those in particular jobs or handling specific duties, the Department of National Defence has noted. In addition, the military does provide extra payment to recruit individuals with particular skills. Article content Various western militaries, facing personnel shortages, have been using retention bonuses to entice individuals to continue to stay in the ranks. Article content On Nov. 22, 2024, the British government announced bonuses equivalent to $54,000 for aircraft engineers who sign up for an additional three years of military service. Privates and lance corporals who have already served four years would be eligible for a new retention bonus, which is the equivalent of $14,000.
